**Core Concept**
Chronic lymphocytic leukemia (CLL) is a type of cancer characterized by the progressive accumulation of dysfunctional lymphocytes in the blood, bone marrow, lymphoid tissues, and other organs. The disease is associated with a poor prognosis, especially when left untreated.

**Why the Correct Answer is Right**
The first-line treatment for CLL involves the use of a class of medications called Bruton's tyrosine kinase (BTK) inhibitors. These drugs target and inhibit the BTK enzyme, which is crucial for the activation, proliferation, and survival of malignant B cells in CLL. The BTK pathway is essential for the signaling and activation of various downstream effectors involved in CLL pathogenesis. Imbruvica (Ibrutinib) is a potent BTK inhibitor that has revolutionized the treatment of CLL by significantly improving patient outcomes.

**Why Each Wrong Option is Incorrect**
**Option A:** Chlorambucil is a chemotherapy agent that has been used in the treatment of CLL, but it is not the preferred first-line treatment due to its lower efficacy and higher toxicity profile compared to BTK inhibitors.
**Option B:** Fludarabine is a purine analog that has been used in combination with other agents in CLL treatment, but it is not the preferred first-line treatment due to its association with severe neutropenia and increased risk of infections.
**Option C:** Rituximab is a monoclonal antibody that targets CD20 on B cells and has been used in the treatment of CLL, but it is not the preferred first-line treatment due to its limited efficacy as a single agent.

**Clinical Pearl / High-Yield Fact**
BTK inhibitors, such as Imbruvica, have significantly improved the treatment outcomes of CLL patients by targeting the malignant B cells and reducing the risk of disease progression and treatment-related complications.

**Correct Answer:** C. Imbruvica.